196 related articles for article (PubMed ID: 30322329)
21. Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors.
Vardhana S; Cicero K; Velez MJ; Moskowitz CH
Oncologist; 2019 Jan; 24(1):86-95. PubMed ID: 30082490
[TBL] [Abstract][Full Text] [Related]
22. Low-dose pembrolizumab induced complete radiologic and molecular response of posttransplant lymphoproliferative disorder presenting as classical Hodgkin lymphoma.
Sim JPY; Au-Yeung R; Kwong YL
Ann Hematol; 2020 Feb; 99(2):385-388. PubMed ID: 31773213
[No Abstract] [Full Text] [Related]
23. An evaluation of brentuximab vedotin as a treatment option for stage III/IV Hodgkin lymphoma.
Choi Y; Diefenbach CS
Expert Rev Hematol; 2019 Oct; 12(10):801-808. PubMed ID: 31432732
[No Abstract] [Full Text] [Related]
24. Programmed Cell Death-One Inhibition Therapy in Classical Hodgkin Lymphoma.
Al-Hadidi SA; Chuang HH; Miranda RN; Lee HJ
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e105-e111. PubMed ID: 33160934
[TBL] [Abstract][Full Text] [Related]
25. Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma.
Koh YW; Jeon YK; Yoon DH; Suh C; Huh J
Tumour Biol; 2016 Jun; 37(6):7507-14. PubMed ID: 26678894
[TBL] [Abstract][Full Text] [Related]
26. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
Ansell SM; Lesokhin AM; Borrello I; Halwani A; Scott EC; Gutierrez M; Schuster SJ; Millenson MM; Cattry D; Freeman GJ; Rodig SJ; Chapuy B; Ligon AH; Zhu L; Grosso JF; Kim SY; Timmerman JM; Shipp MA; Armand P
N Engl J Med; 2015 Jan; 372(4):311-9. PubMed ID: 25482239
[TBL] [Abstract][Full Text] [Related]
27.
Castello A; Grizzi F; Qehajaj D; Rahal D; Lutman F; Lopci E
Leuk Lymphoma; 2019 Feb; 60(2):367-375. PubMed ID: 30032683
[TBL] [Abstract][Full Text] [Related]
28. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C
Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904
[TBL] [Abstract][Full Text] [Related]
29. Hematopoietic stem cell mobilization following PD-1 blockade: Cytokine release syndrome after transplantation managed with ascorbic acid.
Sindel A; Taylor T; Chesney A; Clark W; Fowler AA; Toor AA
Eur J Haematol; 2019 Aug; 103(2):134-136. PubMed ID: 31140644
[TBL] [Abstract][Full Text] [Related]
30. Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.
Zinzani PL; Pellegrini C; Cantonetti M; Re A; Pinto A; Pavone V; Rigacci L; Celli M; Broccoli A; Argnani L; Pulsoni A
Oncologist; 2015 Dec; 20(12):1413-6. PubMed ID: 26500229
[TBL] [Abstract][Full Text] [Related]
31. [Not Available].
Gilardin L; Amorim S; Bernard S; Ravdan O; Thieblemont C; Brice P
Bull Cancer; 2018 Dec; 105 Suppl 1():S50-S58. PubMed ID: 30595199
[TBL] [Abstract][Full Text] [Related]
32. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
Villasboas JC; Ansell S
Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
[TBL] [Abstract][Full Text] [Related]
33. PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher.
Allen PB; Gordon LI
Expert Rev Hematol; 2016 Oct; 9(10):939-49. PubMed ID: 27622603
[TBL] [Abstract][Full Text] [Related]
34. Pembrolizumab for classical Hodgkin's lymphoma.
Burki TK
Lancet Oncol; 2016 Aug; 17(8):e324. PubMed ID: 27397043
[No Abstract] [Full Text] [Related]
35. Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat.
Gautam A; Zhu Y; Ma E; Lee SY; Zagadailov E; Teasell J; Richhariya A; Bonthapally V; Huebner D
Leuk Lymphoma; 2018 Jan; 59(1):69-76. PubMed ID: 28583027
[TBL] [Abstract][Full Text] [Related]
36. On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence?
Colombo MP
Clin Cancer Res; 2017 Oct; 23(20):5999-6001. PubMed ID: 29030331
[TBL] [Abstract][Full Text] [Related]
37. Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma.
Jalali S; Price-Troska T; Bothun C; Villasboas J; Kim HJ; Yang ZZ; Novak AJ; Dong H; Ansell SM
Blood Cancer J; 2019 Feb; 9(3):22. PubMed ID: 30783096
[TBL] [Abstract][Full Text] [Related]
38. Radiotherapy in combination with nivolumab for relapsed/refractory classical Hodgkin lymphoma: About two cases.
de Forceville L; Deau-Fischer B; Franchi P; Arsène-Henry A; Cassou Mounat T; Bouscary D; Kirova YM
Cancer Radiother; 2019 Jun; 23(3):232-239. PubMed ID: 31147173
[TBL] [Abstract][Full Text] [Related]
39. What to Do With Success? The Optimist's Creed in Relapsed Hodgkin Lymphoma.
Issa AK; Westin JR
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):483-487. PubMed ID: 27364263
[TBL] [Abstract][Full Text] [Related]
40. A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine.
Epperla N; Hamadani M
Curr Hematol Malig Rep; 2021 Feb; 16(1):19-24. PubMed ID: 33492560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]